$PTLA The market reaction has floored me, but the results did not. This is an expensive drug(A) and is purchased by hospitals thru the P & T process. There are NO pharmacy departments awash in cash in the freaking fourth quarter. Any purchases of A in the fourth Q screams the importance of this drug. 2019 budgets were written and approved before this drug was FDA approved. Watch first and second Q reports for 2020 AND THEN pass judgement on this company. Anything before then is just too premature and short sighted.